Medical News

RSS

Misonix commences direct to hospital sales of its SonaStar Ultrasonic Surgical Aspirator in the US

Misonix, Inc., (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, today announced the second expansion of its direct sales channel for the United States, which was first disclosed in June 2008.

2 Sep 2009

Positive results from second pivotal phase III trial for Lodotra

Nitec Pharma AG ("Nitec" or "Nitec Pharma"), a Switzerland-based specialty pharma company focused on the development and commercialization of medicines to treat chronic inflammation and pain-related diseases, today announced positive results from the second pivotal phase III trial for its lead product, Lodotra(TM).

2 Sep 2009

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors with high levels of a protein known as GSTM4, which may suppress the effects of chemotherapy.

2 Sep 2009

Patient perception of physician disclosure key to gaining trust

When reporting medical errors, patients' perceptions of their physicians' disclosure may be key to gaining their trust, according to researchers from the Johns Hopkins Bloomberg School of Public Health. However, a positive perception of the disclosure has little effect on the lawsuit risk a physician faces.

2 Sep 2009

Merge Healthcare acquires Confirma

With the completion of its acquisition of Confirma, Inc. today, Merge Healthcare Incorporated (NASDAQ: MRGE) has enhanced its medical imaging capabilities to become a market leader in MRI computer-aided detection (CAD) applications. The combined business now has the capability to widen the global adoption of CAD technology through Merge’s international distribution network, as well as provide broader interoperability of this important tool within the health IT enterprise.

2 Sep 2009

Induced antibodies neutralize HIV-1; recognize peptides encapsulated in liposomes

For the first time, researchers have experimentally induced antibodies that neutralize HIV-1 and simultaneously recognize both HIV-1 envelope protein and lipids. The results were reported by U.S. Military HIV Research Program (MHRP) researchers on Aug. 25 in the online version of AIDS, the official journal of the International AIDS Society.

2 Sep 2009

Members of Independence Blue Cross will receive coverage for the administration costs of the H1N1 vaccine

In an effort to help keep members healthy and flu-free this year, Independence Blue Cross (IBC) will offer coverage for the administration costs of the H1N1 (swine flu) vaccine when it becomes available. In addition IBC will continue to cover seasonal flu vaccine.

2 Sep 2009

Government, medical and community experts to discuss about prevention and detection of viral hepatitis

To address this public health challenge, government, medical and community experts will meet September 10-11 in Washington, D.C. to plan an improved national response to viral hepatitis. The conference "The Dawn of a New Era: Transforming our Domestic Response to Hepatitis B & C" will feature keynote addresses, panel discussions and scientific poster sessions focused on enhancing the prevention and detection of viral hepatitis and improving care for people who are already living with the disease.

2 Sep 2009

New study on behaviour of telomeres during cell division in cancerous human cells

A process that limits the number of times a cell divides works much differently than had been thought, opening the door to potential new anticancer therapies, researchers at UT Southwestern Medical Center report in the Aug. 7 issue of the journal Cell.

2 Sep 2009

LifeVantage granted third patent for Protandim

LifeVantage Corporation, has been granted a third patent for its flagship product Protandim from the United States Patent and Trademark Office. Protandim has been clinically proven in earlier studies to slow the progressive rate of aging by reducing oxidative stress and this new patent further documents Protandim’s® effect on antioxidant enzymes in vivo, describing anti-inflammatory effects such as the lowering of C-reactive protein.

2 Sep 2009

Clinical criteria for mild cognitive impairment proves better for identifying Alzheimer's disease

A new Mayo Clinic study found that the clinical criteria for mild cognitive impairment is better at predicting who will develop Alzheimer's disease than a single memory test. This is one more piece of information to aid in the identification and early treatment of individuals most likely to develop Alzheimer's disease. This study will be presented at the Alzheimer's Association International Conference on Alzheimer's Disease on July 14 in Vienna.

2 Sep 2009

Study reveals that valsartan prevents cardiovascular events in high-risk hypertensive Japanese patients

The KYOTO HEART Study, which took place in Japan between January 2004 and January 2009, shows that the addition of valsartan to conventional antihypertensive treatment to improve blood pressure control is associated with an improved cardiovascular outcome in Japanese hypertensive patients at high risk of CVD events.

2 Sep 2009

Genes that regulate the energy consumption of cells have a different structure and expression in diabetics

Genes that regulate the energy consumption of cells have a different structure and expression in type II diabetics than they do in healthy people, according to a new study from the Swedish medical university Karolinska Institutet published in Cell Metabolism.

2 Sep 2009

T cells influence aggressive immune cells by regulating the chemical environment between cells

University of Michigan scientists say they have uncovered a fundamentally new mechanism that holds in check aggressive immune cells that can attack the body's own cells. The findings open a new avenue of research for future therapies for conditions ranging from autoimmune diseases to organ transplants to cancer.

2 Sep 2009

Research to reverse aging and extend human longevity

Researchers are studying ways of extending our healthy years, perhaps one day reversing the physiological aging process to the point where the human life span is virtually limitless. Is the prospect of living from now into eternity a cherished dream or a fearsome nightmare? In the latest life and health article by Vision.org titled, "Who Wants to Live Forever," the topic of aging and the human life span are discussed further and many questions arise on the topic of becoming immortal.

2 Sep 2009

Actelion launches new 20 mcg/mL Ventavis formulation

Actelion Pharmaceuticals US, Inc., today announced the first commercial sales of a new 20 microgram per milliliter (mcg/mL) formulation of Ventavis(R), for the treatment of New York Heart Association Class III and IV pulmonary arterial hypertension (PAH). This increased strength formulation delivers the same dose of Ventavis in half the volume, which is expected to reduce inhalation time and further support patient compliance.

2 Sep 2009

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Highlights of September's Ophthalmology, the journal of the American Academy of Ophthalmology (Academy), include a 2009 review by the Academy of the safety and efficacy of a widely used corneal transplant procedure and a warning about an unusual but serious reaction to systemic fluoroquinolones, a class of antibiotics used to treat a variety of bacterial infections.

2 Sep 2009

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

Nuvo Research Inc., a Canadian drug development company focused on the research and development of drug products that are delivered to and through the skin using its topical and transdermal drug delivery technologies, and on the development of its immune modulating drug candidate WF10, today announced a co-operative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany for the preclinical and clinical development of WF10 as a potential treatment for Allergic Rhinitis.

2 Sep 2009

New ARRA-funded research on white blood cell functioning

The American Recovery and Reinvestment Act (ARRA) has provided funding for new research to learn more about how white blood cells work. Jonathan Reichner, PhD, of the department of surgery at Rhode Island Hospital has received a grant from the National Institutes of Health with funding through the American Recovery and Reinvestment Act. Reichner's hope is that the research will lead to new immune-enhancing therapies, with potential implications for improvements in both cancer treatment and controlling inflammation accompanying injury and infection.

2 Sep 2009

Nanodiamonds: A novel gene delivery technology

Gene therapy holds promise in the treatment of a myriad of diseases, including cancer, heart disease and diabetes, among many others. However, developing a scalable system for delivering genes to cells both efficiently and safely has been challenging.

2 Sep 2009

Medical News

Misonix commences direct to hospital sales of its SonaStar Ultrasonic Surgical Aspirator in the US

Positive results from second pivotal phase III trial for Lodotra

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Patient perception of physician disclosure key to gaining trust

Merge Healthcare acquires Confirma

Induced antibodies neutralize HIV-1; recognize peptides encapsulated in liposomes

Members of Independence Blue Cross will receive coverage for the administration costs of the H1N1 vaccine

Government, medical and community experts to discuss about prevention and detection of viral hepatitis

New study on behaviour of telomeres during cell division in cancerous human cells

LifeVantage granted third patent for Protandim

Clinical criteria for mild cognitive impairment proves better for identifying Alzheimer's disease

Study reveals that valsartan prevents cardiovascular events in high-risk hypertensive Japanese patients

Genes that regulate the energy consumption of cells have a different structure and expression in diabetics

T cells influence aggressive immune cells by regulating the chemical environment between cells

Research to reverse aging and extend human longevity

Actelion launches new 20 mcg/mL Ventavis formulation

Study reveals that antibiotics used to treat a variety of bacterial infections could cause double vision

Nuvo Research's co-operative drug development project with Fraunhofer Institute for developing WF10

New ARRA-funded research on white blood cell functioning

Nanodiamonds: A novel gene delivery technology

Todd Bauman and Chris Povich

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

Latest News